Consumer medicine information

Aldiq

Imiquimod

BRAND INFORMATION

Brand name

Aldiq

Active ingredient

Imiquimod

Schedule

What is in this leaflet

This leaflet answers some common questions about ALDIQ. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you using ALDIQ against the benefits they expect it will have for you.

If you have any concerns about using this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What ALDIQ is used for

ALDIQ is used to treat:

Solar keratosis (SK) on the face and Superficial Basal Cell Carcinoma (sBCC)

Solar keratoses are thickened, scaly patches of skin caused by too much sun exposure. Solar keratosis is also known as actinic keratosis.

Basal cell carcinoma is a type of skin cancer.

Genital/perianal warts

External genital/perianal warts (condyloma acuminata) are warts that appear on the surface of the penis or vulva (external female sexual organ) and around the anus.

ALDIQ is not recommended for use in patients under the age of 18 years as there have been no studies of its effects in this age group.

ALDIQ cream contains the active ingredient imiquimod. Imiquimod is an immune response modifier. It activates immune cells in the body. The immune cells then proceed to kill and remove the virus-infected or cancer cells. Although the exact way that ALDIQ works is unknown, it is believed to be due to its effects on the immune system.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed it for another reason.

Before using it

When you must not use it

Do not use ALDIQ if you have an allergy to:

any medicine containing imiquimod
any of the ingredients listed at the end of this leaflet

Some of the symptoms of an allergic reaction may include:

shortness of breath
wheezing or difficulty breathing
swelling of the face, lips, tongue or other parts of the body
rash, itching or hives on the skin

Do not use ALDIQ:

on skin where there are open sores or wounds. Do not start using ALDIQ until after the area has healed.
on warts inside the vagina or inside the anus or inside the urethra (where you pass urine). The use of ALDIQ cream on these areas has not been studied.
on areas that are sunburnt.

Do not give this medicine to a child under the age of 18 years. Safety and effectiveness in children younger than 18 years have not been established.

Do not take this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering. If it has expired or is damaged, return it to your pharmacist for disposal.

If you are not sure whether you should start taking this medicine, talk to your doctor.

Before you start to use it

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

Tell your doctor if you have or have had any of the following medical conditions:

if you are or you think you are HIV positive
you have previously used ALDIQ cream or other similar preparations to treat your condition
problems with your immune system
currently have, or in the past have had, any other medical conditions
have had any organ transplants
have molluscum contagiosum (molluscum)

Tell your doctor if you are pregnant or plan to become pregnant or are breast-feeding. Your doctor can discuss with you the risks and benefits involved.

If you have not told your doctor about any of the above, tell them before you start taking ALDIQ.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and ALDIQ may interfere with each other. These include:

immunosuppressive medicines used to suppress your immune system

These medicines may be affected by ALDIQ or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while taking this medicine.

How to take ALDIQ

Follow all directions given to you by your doctor or pharmacist carefully. They may differ from the information contained in this leaflet.

If you do not understand the instructions on the bottle, ask your doctor or pharmacist for help.

How much to use

ALDIQ is used to treat several skin conditions. Your doctor will tell you where to apply ALDIQ cream, how often and for how long to apply it for your condition.

Solar Keratosis
If your doctor has prescribed ALDIQ for the treatment of SK, the usual dosage is once a day, at bedtime, three times a week. For three times a week application, ALDIQ can be applied, for example, on Monday, Wednesday and Friday, or Tuesday, Thursday and Saturday.

Your doctor may tell you to continue applying ALDIQ cream for 4 weeks, followed by a period of 4 weeks without any treatment. Your doctor will then check your skin condition. If any SK lesions remain, the treatment should be repeated for another four weeks.

Alternatively, your doctor may want you to continue applying ALDIQ cream for up to 16 weeks, Each treatment should continue for no more than 16 weeks at a time

Superficial Basal Cell Carcinoma
If your doctor has prescribed ALDIQ for the treatment of sBCC, it should be applied to the affected area once a day at bedtime for five consecutive days per week (Monday to Friday), or as recommended by your doctor. Treatment should continue for 6 weeks unless your doctor tells you otherwise.

External Genital or Perianal Warts
If your doctor has prescribed ALDIQ for the treatment of external genital or perianal warts, it is to be applied once a day, at bedtime, three times a week or as recommended by your doctor.

For three times a week application, ALDIQ can be applied on Monday, Wednesday and Friday; or Tuesday, Thursday and Saturday. Treatment should continue until the warts are completely gone. ALDIQ should not be used for more than 16 weeks at a time. It usually takes 8-10 weeks for your warts to disappear but warts may clear as early as 4 weeks. If your warts reappear, talk to your doctor. If your skin reacts badly to ALDIQ, your doctor may recommend that you stop treatment for a few days. It is not necessary to make up the doses that you missed or to prolong the treatment period.

How to use it

ALDIQ should be applied just before bedtime and left on the skin for 6-10 hours. Sufficient cream should be applied to cover the treatment area.

Talk to your doctor if your condition re-appears after treatment.

Before applying ALDIQ, wash your hands and treatment area with mild soap and water and allow it to dry thoroughly. Open a sachet of ALDIQ and squeeze some cream onto your fingertip.
Apply a thin layer of ALDIQ cream onto the treatment area and rub it gently into the skin until the cream vanishes. For sBCC lesions enough cream should be applied to cover the lesion and about 1cm of surrounding skin. One sachet contains enough cream to cover a treatment area of 20 square centimetres (approximately 3 square inches).
If using the sachet after application of the cream, carefully dispose of the unused ALDIQ cream in the sachet where children cannot reach it. Wash your hands with mild soap and water.
Leave ALDIQ cream on the affected area for 6 to 10 hours. Do not shower or bathe during this time.
After 6-10 hours, the area where ALDIQ cream was applied should be washed with mild soap and water.

While you are using ALDIQ

Do not use more than the recommended amount of ALDIQ cream. A thin layer that completely covers the treatment area and surrounding skin is enough.
Do not cover the treatment area with bandages or other dressings after you have applied ALDIQ cream. Cotton gauze dressings are suitable to use, if needed.

If you are using ALDIQ to treat Solar Keratosis

ALDIQ cream should not be applied in or near the eyes, lips or nostrils.
Do not use sunlamps or tanning beds, and avoid going into the sun as much as possible during treatment with ALDIQ cream. Wear protective clothing if you go outside during daylight.
New SK lesions may develop during treatment with ALDIQ cream. These lesions may resolve during the treatment period. Even though the initial SK lesions may clear with treatment, new lesions may develop in the future and require further treatment. ALDIQ cream is not a cure, since SK is considered to be a chronic skin condition.
There are not enough data to support the use of ALDIQ to treat SK on the hands and arms.
ALDIQ cream should not be applied to an area greater than 25 square centimetres.

If you are using ALDIQ to treat Superficial Basal Cell Carcinoma:

ALDIQ cream should not be applied in or near the hairline, eyes, ears, nose or lips.
Do not use sunlamps or tanning beds, and avoid going into the sun as much as possible during treatment with ALDIQ cream. Wear protective clothing if you go outside during daylight.
Visit your doctor regularly if you are treating more than one sBCC lesion at the same time.

If you are using ALDIQ to treat genital warts:

Genital warts are very contagious, therefore avoid sexual (genital, anal or oral) contact.

If you do decide to have sexual relations, apply ALDIQ cream after, not before, sexual activity. If you have already applied the cream, it should be washed off before sexual activity.

ALDIQ cream may weaken condoms and diaphragms; therefore, the cream should be washed off before using a condom or diaphragm during sexual activity. Alternate forms of contraception should be considered.

The effect of ALDIQ cream on the transmission of genital warts is not known.

Uncircumcised men with warts under the foreskin should pull the foreskin back each day and wash underneath it. If daily washing under the foreskin is not carried out, tightness of the foreskin may occur. Early signs of tightness include swelling and wearing away of the skin, or difficulty in pulling back the foreskin. If these symptoms occur, stop the treatment immediately and call your doctor.

Female patients should take special care if applying ALDIQ cream at the opening of the vagina because local skin reactions on the delicate moist surfaces can result in pain or swelling, and may cause difficulty in passing urine.

Do not use ALDIQ for more than one course if you have problems with your immune system either due to illness or because of the medicines you are already taking. If you think this applies to you, talk to your doctor.

ALDIQ cream has been prescribed for your use only. Do not give it to anyone else even if you think their condition is the same as yours.

If you forget to use it

Skip the application you missed and apply your next treatment when you are meant to.

Otherwise, apply it as soon as you remember, and then go back to applying your medicine as you would normally.

Do not apply a double dose to make up for the dose that you missed. This may increase the chance of you getting an unwanted side effect.

If you are not sure what to do, ask your doctor or pharmacist.

If you have trouble remembering to apply your medicine, ask your pharmacist for some hints.

If you take too much (overdose)

Immediately telephone your doctor or the Poisons Information Centre (telephone 13 11 26) for advice, or go to Accident and Emergency at the nearest hospital, if you think that you or anyone else may have used or swallowed too much ALDIQ. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

Symptoms of an overdose from too much ALDIQ applied topically may result in severe skin reactions.

Symptoms of an overdose from swallowing ALDIQ orally include:

nausea
vomiting
headache
fever
low blood pressure

While you are using ALDIQ

If you are about to be started on any new medicine, remind your doctor and pharmacist that you are taking ALDIQ.

Tell any other doctors, dentists and pharmacists who treat you that you are taking this medicine.

Things you must not do

Do not use ALDIQ to treat any other complaints unless your doctor tells you to.

Do not give your medicine to anyone else, even if they have the same condition as you.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using ALDIQ.

This medicine helps most people with the previously mentioned illnesses, but it may have unwanted side effects in a few people. All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.

Do not be alarmed by the following lists of side effects. You may not experience any of them.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor or pharmacist if you notice any of the following and they worry you:

Application site reactions including redness, wearing away of the skin, flakiness, swelling, hardening under the skin, small open sores, crust that forms during healing, small bubbles under the skin, itching, burning, pain, tenderness, irritation, rash, soreness, stinging, sensitivity, skin colour becomes lighter, bleeding, lumps on the skin, infection and pimples.
Most of these skin reactions are mild to moderate, and are signs that the product is working. If your skin reacts badly or the skin reaction becomes too uncomfortable when using ALDIQ cream, wash the cream off with mild soap and water and contact your doctor. Your doctor may recommend that you stop treatment for a few days.
Flu symptoms, tiredness, fever, headache, diarrhoea, back pain, muscle pain, and swollen glands in the neck, armpit and groin.

Some patients have experienced changes in skin colour (lighter or darker) in the area where ALDIQ cream was applied. These changes may be permanent in some cases.

Tell your doctor or pharmacist if you notice anything that is making you feel unwell.

Other side effects not listed above may also occur in some people.

After using ALDIQ

Storage

Keep your cream in a cool dry place where the temperature stays below 25°C.

Do not store ALDIQ or any other medicine in the bathroom or near a sink. Do not leave it on a windowsill or in the car. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Disposal

If your doctor tells you to stop taking this medicine or the expiry date has passed, ask your pharmacist what to do with any medicine that is left over.

Product description

What it looks like

ALDIQ cream is a white to slightly off white cream, packed in a single-use foil sachet. This is enough cream to cover a treatment area of 20 cm². In Australia ALDIQ cream is supplied in boxes of 6 and 12 sachets.

Ingredients

Each ALDIQ sachet contains 12.5 mg of imiquimod as the active ingredient.

The cream also contains the following inactive ingredients:

benzyl alcohol
cetyl alcohol
glycerol
isostearic acid
methyl hydroxybenzoate
polysorbate 60
propyl hydroxybenzoate
purified water
sorbitan monostearate
stearyl alcohol
white soft paraffin
xanthan gum

Distributor

ALDIQ is distributed in Australia by:

Alphapharm Pty Ltd
Level 1, 30 The Bond
30-34 Hickson Road
Millers Point NSW 2000
www.mylan.com.au

This leaflet was prepared in July 2020.

AUST R 201801

aldiq_cmi\Jul20/00

Published by MIMS September 2020

BRAND INFORMATION

Brand name

Aldiq

Active ingredient

Imiquimod

Schedule

1 Name of Medicine

Imiquimod.

2 Qualitative and Quantitative Composition

Each 250 mg sachet of Aldiq contains 12.5 mg of imiquimod as the active ingredient.

Excipients of known effect.

Hydroxybenzoates.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Aldiq is a white to off-white, oil in water vanishing cream.

4 Clinical Particulars

4.1 Therapeutic Indications

Aldiq is indicated for:
treatment of solar (actinic) keratosis on the face and scalp (see Section 4.4 Special Warnings and Precautions for Use);
primary treatment of confirmed superficial basal cell carcinoma where surgery is considered inappropriate;
treatment of external genital and perianal warts/condyloma acuminata in adults (see Section 4.4 Special Warnings and Precautions for Use).

4.2 Dose and Method of Administration

Before applying Aldiq, the patient should wash the treatment area with mild soap and water and allow the area to dry thoroughly. Aldiq is to be applied to the affected area prior to normal sleeping hours and should be left on the skin for approximately 8 hours (6-10 hours). The cream should be rubbed in until it is no longer visible. Following the treatment period, the cream should be removed by washing the treated area with mild soap and water. During the 6-10 hour treatment period showering or bathing should be avoided. Hand washing before and after cream application is recommended.
Local skin reactions (erythema) at the treatment area are common. These reactions may be due to the pharmacological response of the body's immune system to imiquimod. In clinical studies in patients with superficial basal cell carcinoma (sBCC) the histological clearance following imiquimod therapy was statistically (p < 0.001) higher (91%) in patients with moderate to severe local skin reactions compared to those patients who experienced no or mild skin reactions (54%). Similarly there was a significant association between the intensity of local skin reactions (e.g. erythema) seen during the treatment period and complete clearance of solar (actinic) keratosis. A rest period of several days may be taken if required due to the patient's discomfort or severity of the local skin reaction. These local skin reactions generally decrease in intensity or resolve after cessation of imiquimod cream therapy. Treatment may resume once the reaction subsides. In patients requiring a rest period during treatment with imiquimod it is not necessary to make up the missed doses or to prolong the duration of imiquimod therapy.
Aldiq is provided in single use sachets. A new sachet should be opened for each treatment, and cream from a previously opened sachet should not be used.
The dosing frequency of Aldiq for the treatment of sBCC is different to that for the treatment of solar keratosis and external genital warts.

Solar (actinic) keratosis.

Aldiq is to be applied to a treatment area no larger than 25 cm². The recommended dose per application is one sachet. Treatment should be initiated and monitored by a physician using either of the following two dosage regimens.

Cyclical.

Aldiq may be applied 3 times per week (e.g. Monday, Wednesday and Friday) for four weeks prior to normal sleeping hours, and left on the skin for approximately 8 hours. Sufficient cream should be applied to cover the treatment area. After a 4 week treatment free period, clearance of SKs should be assessed. If any lesions persist, treatment should be repeated for another four weeks.
An interruption of dosing should be considered if intense local inflammatory reactions occur (see Section 4.4 Special Warnings and Precautions for Use) or if infection is observed at the treatment site. In this latter case, appropriate other measures should be taken. Each treatment period should not be extended beyond 4 weeks due to missed doses or rest periods.
If the treated lesion(s) show an incomplete response at the follow-up examination at 4-8 weeks after the second treatment period, a different therapy should be used (see Section 4.4 Special Warnings and Precautions for Use).

Continuous.

Aldiq cream may be applied 3 times per week (e.g. Monday, Wednesday and Friday) for up to 16 weeks. The treatment period should not be extended beyond 16 weeks due to missed doses or rest periods.

Superficial basal cell carcinoma (sBCC).

Aldiq is to be applied once daily for 5 consecutive days per week and the treatment should continue for 6 weeks. Sufficient cream should be applied to cover the treatment area, including one centimetre of skin surrounding the tumour. The clinical outcome of therapy can be determined after regeneration of the treated skin, approximately 6 to 12 weeks after the end of treatment. At this time the skin may appear different from the nonaffected surrounding skin that includes an increase in hypopigmentation and a decrease in the degree of rough/ dry/ scaly skin surface. These changes may be secondary to the appearance of the treated healing target tumour area, contrasting with the surrounding sun damaged skin.
Ten percent (19/185) of patients treated with 5 x/week imiquimod therapy for the treatment of sBCC received rest periods. The median time for rest periods was 4 weeks with a range of 1 to 6 weeks after the initiation of therapy. The average number of doses not received per patient due to rest periods was 7 doses with a range of 2 to 22 doses. There was higher histological clearance in patients treated with imiquimod 5 x/week for 6 weeks who had taken a rest period during treatment (89%) compared to those who did not take a rest period from dosing (81%). No statistically significant difference in the effect of rest periods was noted.

External genital/perianal warts.

Aldiq is to be applied once per day three times per week. Examples of 3 times per week application schedules are: Monday, Wednesday, Friday; or Tuesday, Thursday, Saturday. Treatment should continue until there is total clearance of the genital/perianal warts or for a maximum of 16 weeks. A thin layer of Aldiq is to be applied to the wart area. Each sachet contains sufficient cream to cover a wart area of up to 20 cm²; use of excessive amounts of cream should be avoided. The application site is not to be occluded. Nonocclusive dressings such as cotton gauze or cotton underwear may be used in the management of skin reactions.

4.3 Contraindications

Hypersensitivity to any ingredient.

4.4 Special Warnings and Precautions for Use

Local skin reactions such as erythema, erosion, excoriation/flaking, and oedema are common. Other local reactions such as induration, ulceration, scabbing, and vesicles have also been reported. Most skin reactions are mild to moderate. These reactions may be due to the pharmacological response of the body's immune system to imiquimod. Should severe local skin reactions occur, the cream should be removed by washing the treatment area with mild soap and water. These local skin reactions generally resolve after cessation of therapy with imiquimod and are generally less intense during a second course of therapy. Treatment with imiquimod can be resumed after the skin reaction has subsided. In patients requiring a 'rest period' during treatment with imiquimod it is not necessary to make up the missed doses or to prolong the duration of imiquimod therapy. The use of an occlusive dressing is not recommended with imiquimod. Higher than recommended doses may lead to increased local skin reactions.
Rarely, intense local inflammatory reactions including skin weeping or erosion can occur after only a few applications of imiquimod cream. Local inflammatory reactions may be accompanied, or even preceded, by flu-like systemic signs and symptoms, including malaise, pyrexia, nausea, myalgias and rigors. An interruption of dosing should be considered.
Some reports of localised hypopigmentation and hyperpigmentation following use of imiquimod cream have been received. Follow-up information suggests that these skin colour changes may be permanent in some patients.
From an open label multicentre long-term sustained clearance sBCC study, the following pigmentation outcomes were observed among patients at the final 60 month post-treatment visit. See Tables 1 and 2.
It is thought that the changes noted at the target site and surrounding area may be partly explained by tissue remodelling processes. For example, hypopigmentation may be secondary to regenerated skin at the treated site that has not sustained ultraviolet damage, particularly when compared to the surrounding chronically sun damaged skin.
There is limited clinical experience with imiquimod therapy immediately following the treatment of skin conditions with other cutaneously applied therapy or procedures; therefore imiquimod administration is not recommended until tissue is healed from any previous therapy or procedure. Application to broken skin could result in increased systemic absorption leading to a greater risk of adverse events.
Imiquimod, as an immune response modifier, has the potential to exacerbate inflammatory conditions of the skin, including chronic graft versus host disease.
Rare reports have been received of exacerbation of autoimmune conditions (see Section 4.8 Adverse Effects (Undesirable Effects)).
Imiquimod should be used with caution in organ transplant patients and in patients with pre-existing autoimmune conditions (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions). In these patients, consideration should be given to balancing the benefit of treatment with Aldiq with the risk associated with the possibility of organ rejection or graft versus host disease or a possible worsening of the autoimmune condition respectively.
Imiquimod should be used with caution in patients with reduced haematological reserve.
The excipients methyl hydroxybenzoate, propyl hydroxybenzoate, cetyl alcohol and stearyl alcohol may cause allergic reactions.

Solar (actinic) keratosis (SK).

Lesions clinically atypical for SK or suspicious for malignancy should be biopsied to determine appropriate treatment.
Imiquimod has not been evaluated for the treatment of solar keratoses on the eyelids, the inside of the nostrils or ears, or the lip area inside the vermilion border. Contact with the eyes, lips and nostrils should be avoided.
Imiquimod is not recommended for the treatment of SK lesions with marked hyperkeratosis or hypertrophy as seen in cutaneous horns.
During therapy and until healed, affected skin is likely to appear noticeably different from normal skin. Local skin reactions are common but these reactions generally decrease in intensity during therapy or resolve after cessation of imiquimod cream therapy. There is an association between the complete clearance rate and the intensity of local skin reactions (e.g. erythema). These local skin reactions may be related to the stimulation of local immune response. If required by the patient's discomfort or the intensity of the local skin reaction, a rest period of several days may be taken. Treatment with imiquimod cream can be resumed after the skin reaction has moderated.
Each treatment period should not be extended beyond 4 weeks due to missed doses or rest periods.
The clinical outcome of therapy can be determined after regeneration of the treated skin, approximately 4-8 weeks after the end of treatment.
No clinical experience exists with the use of imiquimod in immunocompromised patients.
The safety and efficacy of imiquimod in the retreatment of residual solar keratoses has not been established. There are limited data of imiquimod on recurrence of SK (see Section 4.8 Adverse Effects (Undesirable Effects)). No data are available on retreating solar keratoses that have cleared after one or two courses of treatment and subsequently recur, and any such use is therefore not recommended.
Exposure to natural or artificial sunlight should be avoided or minimised during use of imiquimod (see Section 4.4 Special Warnings and Precautions for Use, Superficial basal cell carcinoma (sBCC)). During treatment, subclinical SK lesions may become apparent in the treatment area and may subsequently resolve (see Section 4.8 Adverse Effects (Undesirable Effects)). There are inadequate data to support the use of imiquimod on the hands and arms, and therefore it should not be used in these areas. Imiquimod should not be used in an area greater than 25 cm² due to the potential to cause local skin reactions (see Section 4.8 Adverse Effects (Undesirable Effects)).

Superficial basal cell carcinoma (sBCC).

The diagnosis of sBCC should be confirmed by biopsy or specialist opinion before starting treatment and the patient should be carefully followed up after treatment to ensure that the tumour has been eradicated. The safety and efficacy of imiquimod have not been established for other types of basal cell carcinomas (BCC), including nodular and morpheaform (fibrosing or sclerosing) types.
Imiquimod is not recommended for treatment of BCC subtypes other than the superficial variant (i.e. sBCC).
Imiquimod has not been evaluated for the treatment of sBCC within 1 cm of the hairline, eyes, nose, mouth or ears.
Exposure to sunlight (including sunlamps) should be avoided or minimised during use of imiquimod because of concern for heightened sunburn susceptibility. Patients should be warned to use protective clothing when using imiquimod. Patients with sunburn should be advised not to use imiquimod until fully recovered. Patients who may have considerable sun exposure (e.g. due to their occupation), and those patients with inherent sensitivity to sunlight should exercise caution using imiquimod. Phototoxicity has not been adequately assessed. The enhancement of ultraviolet carcinogenicity is not necessarily dependent on phototoxic mechanisms. Despite the absence of observed phototoxicity in humans (see Section 4.8 Adverse Effects (Undesirable Effects)), imiquimod shortened the time to skin tumour formation in an animal photo carcinogenicity study (see Section 4.6 Fertility, Pregnancy and Lactation; Section 5.3 Preclinical Safety Data). Therefore, it is prudent for patients to minimise or avoid natural or artificial sunlight exposure.
In a limited number of patients the histological clearance rate for tumours > 7.25 cm² (n = 17) was lower (65%) than that for tumours (n = 49) ranging from 2-7.25 cm² in size (90%) (see Section 4.8 Adverse Effects (Undesirable Effects), Clinical trial data). Imiquimod has not been evaluated for locally recurrent superficial BCC or after initial treatment has failed.
Data on the safety of treating multiple sBCC lesions simultaneously in an individual patient is limited to one clinical study (n = 67) in which the maximum number of lesions was six (see Section 4.8 Adverse Effects (Undesirable Effects), Clinical trial data). While no new safety issues emerged with the higher doses administered in this study, close monitoring of such patients is advised.
There is no experience in treating basal cell carcinoma associated with xeroderma pigmentosum, Gorlin's syndrome or immunosuppressive therapy.
No clinical experience exists with the use of imiquimod in immunocompromised patients.
No clinical experience exists in patients with recurrent and previously treated BCCs, therefore use for previously treated tumours is not recommended.

External genital/perianal warts.

Imiquimod should not be used to treat urethral, intravaginal, cervical, rectal, or intra-anal warts due to the unknown local tolerance and potential systemic absorption. Imiquimod has not been evaluated for the treatment of warts in these locations.
Special care should be taken if applying imiquimod at the opening of the vagina, as local skin reactions on the mucosal surfaces can result in pain or swelling, and may cause difficulty in passing urine.
This may sometimes require emergency catheterisation and treatment of the affected area.
Treatment beyond 16 weeks and repeat treatment with imiquimod after initial successful therapy have not been studied.
Repeat treatment with imiquimod is not recommended in immunocompromised patients.
The efficacy of imiquimod for the treatment of genital warts in patients with HIV has not been studied adequately. Limited information suggests that efficacy may be reduced in these patients. The implications for patients with impairment of the immune system for other reasons are not known.
The effect of imiquimod on the transmission of genital/perianal warts is unknown. Sexual (genital, anal, oral) contact should be avoided while the cream is on the skin. Imiquimod may weaken condoms and vaginal diaphragms, therefore concurrent use with imiquimod is not recommended. Alternate forms of contraception should be considered.
Uncircumcised males treating warts under the foreskin should retract the foreskin and clean the area daily, as foreskin tightness and stricturing have been reported with the administration of imiquimod. Early signs of stricture may include local skin reactions (e.g. erosion, ulceration, oedema, induration), or increasing difficulty in retracting the foreskin. If these symptoms occur, the treatment should be stopped immediately.
Imiquimod therapy should not be initiated in tissues where open sores or wounds exist until after the area has healed.

Use in the elderly.

Of the 185 patients in the 5 x/week treatment groups of clinical studies evaluating the treatment of sBCC with imiquimod, 65 patients (35%) were 65 years and older, while 25 patients (14%) were 75 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. No other clinical experience has identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Paediatric use.

The safety and efficacy of imiquimod in patients below the age of 18 years have not been established. Use in this patient population is therefore not recommended.
Imiquimod should not be used in patients with molluscum contagiosum.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

In vitro plasma protein binding of imiquimod was in the range of 90-95% and was independent of concentrations in the therapeutic range. Although no clinical trials were performed to determine drug-drug interactions of imiquimod, an in vitro plasma protein binding study demonstrated that protein binding of imiquimod was not affected by paracetamol, amoxicillin, cefalexin, chlorpromazine, cimetidine, diazepam, erythromycin, flecainide, ibuprofen, morphine, phenytoin, prednisolone, theophylline, warfarin. Therefore, coadministration of topically applied imiquimod with any of these compounds would not affect systemic safety of imiquimod nor the coadministered drugs due to competitive protein binding. Furthermore, in view of the limited systemic availability following topical administration of imiquimod, it is unlikely that drug-drug interactions will occur.
Due to its immunostimulating properties, imiquimod should be used with caution in patients who are receiving immunosuppressive medication (see Section 4.4 Special Warnings and Precautions for Use).

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Daily oral administration of imiquimod to rats at doses up to 8 times the recommended human dose on a mg/m² basis throughout mating, gestation, parturition and lactation demonstrated no impairment of reproduction.
(Category B1)
Imiquimod was not teratogenic in rats dosed orally or in rabbits dosed intravenously. In rats, at a maternally toxic dose (28 times the maximum human dose on a mg/m² basis), reduced pup weights and delayed ossification were observed. There are no adequate and well controlled studies in pregnant women. Imiquimod is not recommended for use during pregnancy.
It is not known whether topically applied imiquimod is excreted in animal or human milk. No adverse effects were demonstrated in developmental studies with offspring of rats treated with imiquimod during gestation and lactation at doses up to 8 times the maximum human dose on a mg/m² basis. Imiquimod is not recommended for use during lactation as there are no data available in this population.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Dermal safety studies involving induction and challenge phases produced no evidence that imiquimod cream causes photoallergenicity or contact sensitisation in healthy skin. However, cumulative irritancy testing revealed the potential for imiquimod to cause irritation, and in the clinical studies local site reactions (LSRs) were reported in a significant percentage of study patients. Phototoxicity testing was incomplete as wavelengths in the UVB range were not included and imiquimod cream has peak absorption in the UVB range (320 nanometre) of the light spectrum.
The LSRs were systematically collected at every visit and assessed and recorded separately from adverse events. They were only recorded as AEs if they extended beyond the surrounding area(s) (i.e. greater than 5 cm beyond the margins of the treatment area[s]). As such, the incidence of each of the predefined LSRs is, perhaps, higher than what might have been expected if the event had been captured based on spontaneous subject reporting or observed adverse events as the AEs.

Clinical trial data.

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in general practice. The adverse reaction information from clinical studies does however provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
a) General description.

Solar (actinic) keratosis.

In the pivotal trials with 3 times per week dosing for up to 2 courses each of 4 weeks, 56% of imiquimod patients reported at least one adverse event. The most frequently reported adverse event from these trials judged probably or possibly related to imiquimod was application site reactions (22% of imiquimod treated patients). Some systemic adverse reactions, including myalgia (2%) were reported by imiquimod treated patients.
Patient reported adverse reactions from 252 patients treated with imiquimod in vehicle controlled phase III clinical studies for solar keratosis are presented below. These adverse events are considered at least possibly causally related to treatment with imiquimod.

Superficial basal cell carcinoma.

In trials with 5x per week dosing 58% of patients experienced at least one adverse event. The most frequently reported adverse events from the trials judged probably or possibly related to imiquimod are application site disorders, with a frequency of 28.1%. Some systemic adverse reactions, including back pain (1.1%) and influenza-like symptoms (0.5%) were reported by imiquimod patients.
Patient reported adverse reactions from 185 patients treated with imiquimod in placebo controlled phase III clinical studies for superficial basal cell carcinoma are presented in Table 3. These adverse events are considered at least possibly causally related to treatment with imiquimod.

External genital warts.

In the pivotal trials with 3 times a week dosing, the most frequently reported adverse drug reactions judged to be probably or possibly related to imiquimod treatment were application site reactions at the wart treatment site (33.7% of imiquimod treated patients). Some systemic adverse reactions, including headache (2.1%), influenza-like symptoms (0.3%), and myalgia (1.4%) were also reported.
Patient reported adverse reactions from 2292 patients treated with imiquimod cream in placebo controlled and open clinical studies are presented in Table 3. These adverse events are considered at least possibly causally related to treatment with imiquimod.
b) Tabular listing of adverse events. Adverse events are listed in the following table in CIOMS frequency categories: very common (greater than 10%), common (1%-10%), uncommon (0.1%-1%).
Lower frequencies from clinical trials are not reported here. See Table 3.

c) Frequently occurring adverse events.

Solar (actinic) keratosis.

In clinical trials of imiquimod cream 3x weekly for 4 or 8 weeks 56% of imiquimod patients reported at least one adverse event. The most frequently occurring application site reactions were itching at the target site (14%) and burning at the target site (5%). Severe erythema (24%) and severe scabbing and crusting (20%) were very common. Local skin reactions, such as erythema, are probably an extension of the pharmacological effect of imiquimod cream. See Section 4.2 Dose and Method of Administration; Section 4.4 Special Warnings and Precautions for Use for information on rest periods.
Skin infections during treatment with imiquimod have been observed. While serious sequelae have not resulted, the possibility of infection in broken skin should always be considered. See Table 4.

These LSRs peaked at 4 weeks. Their incidence during the second course of treatment was generally lower than during the first course.

Superficial basal cell carcinoma.

Investigators of the placebo controlled clinical trials were required to evaluate protocol mandated clinical signs (skin reactions). These protocol mandated clinical sign assessments indicate that severe erythema (31%) severe erosions (13%) and severe scabbing and crusting (19%) were very common in these trials with imiquimod cream applied 5x weekly. Local skin reactions, such as erythema, are probably an extension of the pharmacological effect of imiquimod cream.
The data described below reflect exposure to 5 x/week imiquimod cream for 6 weeks or vehicle in 364 patients enrolled in two double blind, vehicle controlled studies. The population ranged from 31 to 89 years of age (median 60 years) and 65% had Fitzpatrick skin types I or II. The incidence and severity of local skin reactions that occurred during controlled studies is shown in Table 5.

External genital/perianal warts.

In controlled clinical trials the most frequently observed adverse events were local inflammatory skin reactions, which may be due to the pharmacological response of the body's immune system to imiquimod. These reactions were usually mild to moderate in intensity, although some were severe. Overall, in clinical studies applying imiquimod cream three times per week, 1.2% (4/327) of patients discontinued treatment due to local skin/application site reactions.
To accurately report the incidence of the local skin reactions among patients in placebo controlled studies of imiquimod cream applied 3 x/week for 16 weeks, the investigators were requested to specifically assess erythema, oedema, induration, vesicles, erosion, ulceration, excoriation/flaking, and scabbing at the wart site and remote sites (defined as skin areas other than where study cream was applied). The incidence of these local skin reactions assessed by the investigator during the entire study period are summarised in Table 6.

d) Adverse events applicable to all indications. Reports have been received of localised hypopigmentation and hyperpigmentation following imiquimod use. Follow-up information suggests that these skin colour changes may be permanent in some patients.
Clinical studies investigating the use of imiquimod for the treatment of solar keratosis have detected a 0.4% (5/1214) frequency of alopecia at the treatment site or surrounding area. Postmarketing reports of suspected alopecia occurring during the treatment of sBCC and EGW have been received.
Reductions in haemoglobin, white blood cell count, absolute neutrophils and platelets have been observed in clinical trials. These reductions are not considered to be clinically significant in patients with normal haematological reserve. Patients with reduced haematological reserve have not been studied in clinical trials. Reductions in haematological parameters requiring clinical intervention have been reported from postmarketing experience.
Rare cases of remote site dermatological drug reactions, including erythema multiforme, have been reported from clinical trials. Serious skin reactions reported from postmarketing experience include erythema multiforme, Stevens-Johnson syndrome and cutaneous lupus erythematosus.
In clinical studies, psoriasis was recorded as a pre-existing condition in 24 imiquimod subjects. Of those, an exacerbation of psoriasis causally related to imiquimod was reported in 6 subjects.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Overdose of imiquimod in humans is unlikely due to minimal percutaneous absorption. Animal studies reveal a rabbit dermal lethal imiquimod dose of greater than 1600 mg/m² (5000 mg/kg). Persistent topical overdosing of imiquimod could result in severe local skin reactions. These usually subside within 2 weeks of imiquimod discontinuation.
Following ingestion of a single 200 mg oral imiquimod dose (corresponds to the content of approximately 16 sachets), nausea, emesis, headache and fever can occur. The most clinically serious adverse event reported following multiple oral imiquimod doses of > 200 mg was hypotension, which resolved following oral or intravenous fluid administration.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Imiquimod is an immune response modifier. Imiquimod has been shown to stimulate the innate and adaptive immune response through the induction of interferon-α (IFN-α) and other cytokine production by multiple cell types (e.g. macrophages; monocytes; B cells; plasmacytoid dendritic cells (pDC)). pDCs, a major subset of (pre)DCs, have the highest expression of Toll-like receptor-7 (TLR7) amongst DC subsets.
Imiquimod activates immune cells by engaging TLR7 and (to a lesser extent) Toll-like receptor-8 (TLR8) signalling, and consecutively, activation of nuclear factor-kappa B (NF-κB) and induction of pro-inflammatory cytokines, chemokines and other mediators such as IFN-α, tumour necrosis factor (TNF)α, interleukin (IL)-2, IL-6, IL-8, IL-12.
Imiquimod induces an increase in markers for IFN-γ and the interferon inducible gene product 2'5'-oligoadenylate synthetase at the treatment site.
Imiquimod has no direct in vitro antiviral activity. The antiviral activity is indirect through cytokine induction of IFN-α and immune activation. In addition, HPVL1 mRNA and HPV DNA are significantly decreased following treatment. However the clinical relevance of these findings is unknown.
As well as enhancing proinflammatory cytokine secretion from pDCs, imiquimod enhances costimulatory marker expression, increase CCR7 (e.g. enabling migration into lymphatic vessels and into lymph nodes) and improve pDC viability.
Another important effect of imiquimod is to encourage pDC maturation, however the extent of pDC migration to skin is not well defined.
It is also possible that imiquimod can stimulate the proliferation of B cells in vitro.
Independent of TLR-7 and TLR-8, imiquimod appears to interfere with adenosine receptor (AR) signalling pathways, particularly A2A, and receptor independent reduction of adenylyl cyclase activity may augment the proinflammatory activity of imiquimod.
Imiquimod appears to exert some proapoptotic activity against tumour cells.
Two mechanism of action studies were performed to determine the nature of cellular immune responses early in the course of treatment or at the time of tumour erosion in superficial basal cell carcinoma tumours and surrounding tissue after treatment with imiquimod. The studies focused on the survival mechanisms of the tumour cells, and whether imiquimod therapy alters the immune cell composition in the area of the tumour, thereby causing basal cell carcinoma tumour cells to be more susceptible to killing. The results of these studies are consistent with a mechanism of action that involves immune mediated tumour cell destruction.
These studies showed that imiquimod cream stimulates the infiltration of tumour destructive cells (T-cell lymphocytes, dendritic cells and macrophages) at the superficial basal cell carcinoma lesions and reduces the defence mechanism of the tumour.
Superficial basal cell carcinoma and solar keratosis occurs in patients with chronic UV damaged skin.
A study in solar keratosis patients evaluating the systemic exposure to imiquimod following topical applications of 12.5 mg from one sachet of imiquimod to facial lesions, or 25 mg from two sachets of imiquimod to scalp lesions, or 75 mg of imiquimod to lesions on both hands and arms three times per week for 16 weeks showed that after 16 weeks of dosing serum imiquimod levels were low, reflecting minimal percutaneous absorption of imiquimod (see Section 5.2 Pharmacokinetic Properties). The levels of biomarkers sensitive to imiquimod increased up to approximately 2 to 15 fold over baseline. These biomarkers included interleukin-1 receptor antagonist, interferon-α and 2'5'-oligoadenylate synthetase. The increases in biomarkers were associated with a small number of systemic adverse events.
The mechanism of the immune stimulation was evaluated in SK patients treated with imiquimod. Imiquimod treatment was associated with increases in lymphocytes, dendritic cells, macrophages, and cells bearing activation markers in the SK lesions. Statistically significant differences between baseline and week 2 biomarker levels were seen for the imiquimod treatment for CD3, CD4, CD8, CD11c, CD86/CD11c double stain, CD68, class II human leukocyte antigen-DR, and terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate nick end labelling (TUNEL). The cellular infiltration observed in the imiquimod treated SK lesions was consistent with activation of the innate and acquired immune responses.

Clinical trials.

Solar (actinic) keratosis.

One or two courses of 4 weeks treatment.

The efficacy of imiquimod applied 3 times per week for one or two courses of 4 weeks, separated by a 4 week treatment free period, was studied in two double blind vehicle controlled clinical trials. Patients had clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic SK lesions on the balding scalp or face within a contiguous 25 cm² treatment area. 4-8 SK lesions were treated. The complete clearance rate, defined as the percentage of patients with no clinically visible SK lesions in the treatment area for the two trials combined, was 54.4% (137/252) for imiquimod and (8.3%) (21/253) for vehicle, resulting in a significant difference of 46.1% (CI 39.0%, 53.1%).
One year data from two combined observational studies indicate a recurrence rate of 27% (35/128 patients) in those patients who became clinically clear after one or two courses of treatment. The recurrence rate for individual lesions was 5.6% (41/737). Corresponding recurrence rates for vehicle were 47% (8/17 patients) and 7.5% (6/80 lesions). The rate of progression to squamous cell carcinoma (SCC) was reported in 1.6% (2/128 imiquimod patients).
There are no data on recurrence and progression rates beyond 1 year.

Up to 16 weeks treatment.

A total of 1214 patients were enrolled in 5 phase III double blind, randomised, vehicle controlled, parallel group, multicentre studies that evaluated the efficacy and safety of imiquimod for the treatment of solar keratosis (SK). In three of the studies patients with SK were treated with imiquimod or vehicle cream once daily 3 times per week for up to 16 weeks. In the remaining two studies patients with SK were treated with imiquimod 5% or vehicle cream once daily 2 times per week for up to 16 weeks. Patients with 4-8 SK lesions within a 25 cm² contiguous treatment area on either the face or scalp were enrolled and randomised to active or vehicle treatment. The primary variable was the complete (100%) clearance rate, defined as the proportion of patients with no SK lesions in the treatment area at 8 weeks post treatment. This included clearance of all baseline lesions as well as any new or subclinical SK lesions which appeared in the treatment area during treatment. The secondary variable was the partial clearance rate, defined as the proportion of patients with at least a 75% reduction in the number of SK lesions in the treatment area at 8 weeks post treatment. In all but one study clearance was determined by clinical assessment. In the remaining study (EU 3 x/week study), clearance was determined by both clinical and histological assessment. In this study the clinical diagnosis of SK lesion clearance was confirmed by histology for 94.2% of subjects. The complete and partial clearance rates are shown in Tables 7 and 8.

The overall reduction of individual SK lesions in the imiquimod group was 78.8% (708/898 lesions) in the EU 3 x/week study, 74.0% (1000/1352 lesions) in the combined US 3 x/wk studies and 70.2% (851/1212 lesions) in the combined US 2 x/wk studies versus 8.7% (67/766 lesions), 24.6% (347/1409 lesions) and 17.0% (213/1255 lesions) respectively for the vehicle group.
A statistically significant trend was observed between the complete clearance rate and severity of local skin reactions (erythema) for the imiquimod treated patients in the phase III studies. The complete clearance rate tended to increase as the intensity level of erythema increased. Based on the appearance of local skin reactions (LSRs) and their association with clearance, LSRs can be considered an extension of the pharmacological effects of imiquimod cream.
Subclinical SK lesions may become apparent in the treatment area during treatment with imiquimod. The proportion of imiquimod treated patients with an increase in their SK lesion count relative to the number present at baseline during the course of treatment, and the proportion that were completely clear 8 weeks post-treatment is presented in Table 9.

Imiquimod treated patients with an increase in SK lesion counts had higher clearance rates compared to imiquimod patients with no increase.
The pharmacodynamic response seen with imiquimod treatment may have led to unblinding of the studies to some extent, and the magnitude of the efficacy reported may be an overestimate of the real value.
Information from an observational follow-up study of patients who had demonstrated complete clearance of their SK lesions at 8 weeks post-treatment showed that 24.7% (19/77) of the imiquimod treated patients in the 3 x/week dosing group and 42.6% (23/54) of the imiquimod treated patients in the 2 x/week dosing group had a recurrence of SK within the treatment area after a median follow-up of 16.6 months. Overall, in those subjects who experienced a recurrence of SK, the median number of lesions that recurred was 1.
The above two regimens for the treatment of solar keratosis have not been compared directly in clinical trials and it is, therefore, not known how they directly compare with respect to efficacy or safety.
The potential additive therapeutic effects of using sunscreens simultaneously with imiquimod have not been explored systematically in clinical trials.
Superficial basal cell carcinoma. In two double blind, vehicle controlled studies, 364 patients with superficial basal cell carcinoma (sBCC) were treated with imiquimod or vehicle cream once daily for 5 consecutive days per week (5 x/week) for 6 weeks. Patients with biopsy confirmed sBCC tumour were enrolled and randomized in a 1:1 ratio to active or vehicle treatment. On a scheduled dosing day, the study cream was applied to lesions prior to normal sleeping hours; dosing continued for a total of 6 weeks. Twelve weeks after the last scheduled application of study cream, the clinical response of each patient was evaluated. At that time the entire target tumour area was excised and examined histologically for the presence of tumour. The complete clearance rate for the imiquimod treated group was 75% compared to 2% in the vehicle treated group. The complete clearance rate consisted of all patients whose histological response showed no evidence of tumour excluding those where clinical appearances were suspicious of tumour presence and this appearance was not explained by the histological findings. The histological clearance rate for the imiquimod treated group (82%) was significantly greater (p < 0.001) than the clearance rate of the vehicle treated group (3%). The histological clearance rate included patients whose histological response showed no evidence of tumour. The histological clearance rate following imiquimod therapy was statistically (p < 0.001) higher (91%) in patients with moderate to severe local skin reactions compared to those patients who experienced no or mild local skin reactions (54%).
In an open label, multicentre study evaluating the long-term sustained clearance rate in patients with sBCC treated with imiquimod once daily for 5 consecutive days per week (5 x/week) for 6 weeks, a clinical evaluation of treatment response was used as the sole measure of treatment outcome to represent clinical practice setting. At the 12 week posttreatment assessment 90% (163/182) of patients had no clinical evidence of sBCC at the target tumour site. At 12 months follow up 94% of patients who were clear at the 12 week post-treatment assessment remained clear. The long term recurrence rate following imiquimod treatment is unknown, and it is recommended that patients have regular follow-up to confirm sustained clearance.
In an open label uncontrolled study in subjects (n = 66) with tumours ranging from 2-48 cm² treated with imiquimod once daily 5 days per week for 6 weeks, the histological clearance rate was 83%. Analysis of tumour size in relationship to clearance rates showed some decrease in clearance rates when the tumour size was > 7.25 cm² (see Section 4.4 Special Warnings and Precautions for Use).
In a second open label uncontrolled study in subjects with multiple (2-6) tumours treated with imiquimod once daily 5 days per week for 6 weeks (n = 36), 47% of subjects were histologically negative for all sBCC's treated. Of the individual sBCC's treated (n = 111), 77% were histologically clear.
Nodular basal cell carcinoma. The efficacy of imiquimod in the treatment of nodular BCC has not been adequately established.
External genital/perianal warts. In a double blind, placebo controlled clinical trial (n = 209), imiquimod applied three times a week for the treatment of genital and perianal warts achieved wart clearance rates (50%) that were statistically significantly greater than the placebo control (11%). The percentage of patients treated with imiquimod achieving total clearance was 72% for females and 33% for males. The percentage of patients achieving partial wart area (> 50%) reduction was 85% for females and 70% for males. The median baseline wart area was 69 mm² (range 8 to 5525 mm²). Visible reduction in wart area occurred as early as the second week of treatment. Total wart clearance occurred as early as 4 weeks and some patients required 16 weeks. The median time to total wart clearance was 10 weeks. A low percentage (13%) of the patients treated with imiquimod who achieved total clearance of their warts experienced a recurrence of their warts during the 12 week follow-up period. See Table 10.

5.2 Pharmacokinetic Properties

In patients with solar keratosis (n = 58), only minimal systemic absorption of imiquimod across the affected skin was observed when imiquimod cream was applied three times per week for 16 weeks. At the end of week 16, a urinary recovery of imiquimod and its metabolites of less than 0.6% of the applied dose were observed in these patients.
Peak serum imiquimod concentrations were observed between 9 and 12 hours and were approximately 0.1, 0.2 and 1.6 nanogram/mL for applications to face (12.5 mg imiquimod or 1 sachet), scalp (25 mg or 2 sachets) and hands/arms (75 mg or 6 sachets) respectively.
A small number of systemic adverse events such as 'flu-like' symptoms that could be associated with innate immune response activity (IFN induction) were reported (e.g. flu-like symptoms 4/58). These were mild and no dose response was observed. An apparent terminal half-life of imiquimod was approximately 10 times greater than the 2 hour half-life seen following subcutaneous application, suggesting prolonged retention of imiquimod in the skin for greater than 24 hours after the cream is removed.
Percutaneous absorption of imiquimod following topical administration of imiquimod has been studied over a wide spectrum of skin types, from keratinised skin of genital warts to intact healthy skin to the lesions of sun damaged skin. The results from these studies should also encompass the likely pharmacokinetics of imiquimod across the affected skin of patients with sBCC. The percutaneous penetration of imiquimod following topical application of imiquimod for 8-12 hours was minimal (< 1%) across the intact skin of healthy subjects and the affected skin of subjects with either genital warts or solar keratosis. Because of this low percutaneous absorption, serum levels of imiquimod and its metabolites were low or undetectable in these subjects. These low imiquimod serum levels indicate that the topical use of imiquimod in patients with superficial basal cell carcinoma should not pose any systemic safety concern.
In subjects with intact healthy skin (n = 6), less than 0.9% of a single topically applied 5 mg dose of [C₁₄] labelled imiquimod was recovered in the urine and faeces. Radioactive imiquimod levels could not be quantified in the serum of these subjects. In patients with genital/perianal warts (n = 12) treated with imiquimod cream three times a week for 16 weeks median imiquimod peak serum concentrations of approximately 0.1 and 0.3 nanogram/mL were observed during the study. Median urinary recoveries of imiquimod and its metabolites following the last dose of week 16 were approximately 0.09% and 1.2% of the dose for males and females respectively, indicating only minimal systemic absorption of imiquimod.

5.3 Preclinical Safety Data

Genotoxicity.

Imiquimod was without effect in a bacterial gene mutation assay (Ames test), chromosome damage assays in vitro and in vivo, and in a cell transformation assay.

Carcinogenicity.

Two year carcinogenicity studies in Wistar rats (up to 3 mg/kg/day orally) and CD-1 mice (up to 4.5 mg/kg applied topically 3 times per week) showed no evidence of a carcinogenic effect in male and female rats and female mice. Incidences of liver tumours were increased in male mice exposed to the highest dose. Systemic exposure was not measured in the mouse dermal carcinogenicity study, although it is estimated that at the high dose the absorbed dose was greater than that in humans.
A photocarcinogenicity study in hairless albino mice showed that dermal administration of the vehicle alone enhanced the development of UVR induced skin tumours. Dermal administration of 0.03%, 0.1% and 0.3% imiquimod in the vehicle resulted in a slight dose related reduction in UVR induced skin tumour development compared with the vehicle alone group. Exposure to the sun of treated skin areas should be minimised (see Section 4.4 Special Warnings and Precautions for Use).

6 Pharmaceutical Particulars

6.1 List of Excipients

Aldiq also contains the following inactive ingredients: benzyl alcohol, cetyl alcohol, glycerol, isostearic acid, methyl hydroxybenzoate, polysorbate 60, propyl hydroxybenzoate, purified water, sorbitan monostearate, stearyl alcohol, white soft paraffin and xanthan gum.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Do not freeze.

6.5 Nature and Contents of Container

Container type.

Sachet (other plastic laminate/Al).

Pack sizes.

6, 12.
Some strengths, pack sizes and/or pack types may not be marketed.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

6.7 Physicochemical Properties

Chemical structure.

Imiquimod is an odourless, white to off white crystalline solid.
Chemical name: 1-(2-methylpropyl)-1H-imidazo [4,5-c]quinolin-4-amine.
Molecular formula: C₁₄H₁₆N₄.
Molecular weight: 240.3.

CAS number.

99011-03-06.

7 Medicine Schedule (Poisons Standard)

S4 (Prescription Only Medicine).

Log in

Consumer medicine information

Aldiq

Imiquimod

Keep track of your medicines

BRAND INFORMATION